Ireland Pharma Tax Threatened by Trump Accusations
Trump’s Stance on US Pharma in Ireland: profit Shifting vs. Plant Closures
Table of Contents
- Trump’s Stance on US Pharma in Ireland: profit Shifting vs. Plant Closures
- TrumpS Stance on US Pharma in Ireland: Q&A
- 1. What is donald Trump’s issue with US pharmaceutical companies in Ireland?
- 2. Will US pharma companies close plants in Ireland due to Trump’s stance?
- 3. What is “profit shifting” or “phantom exports,” and how does it relate to US pharma in Ireland?
- 4. How vulnerable is Ireland to changes in US tax policy regarding pharma companies?
- 5. How could Trump address the trade imbalance with Ireland?
- 6. What is the potential impact on jobs in the Irish pharmaceutical sector?
- 7. What do Irish exports of medicine look like?
- 8.How much corporate tax does ireland collect, and what role do US companies play?
- Key Information Summary: US Pharma in Ireland
Experts suggest that US pharmaceutical companies operating in Ireland are more inclined to shift profits back to the United States rather than shutter manufacturing plants, following accusations from Donald Trump that Ireland is “stealing” American tax revenue and jobs.
Aidan Regan, a professor of political economy at University College Dublin, contends that the former US president is justified in highlighting the trade imbalance resulting from the presence of US pharmaceutical firms in Ireland, asserting that these warning signs have been evident for years.
Regan stated, “Trump is right. And it was refreshingly honest what he said. I imagine the Irish government would feel the same way if it was Irish companies all over the globe making all their sales in Ireland but shipping their profits offshore.”
During a meeting with the Irish Taoiseach, Micheál Martin, Trump “repeatedly took aim at Ireland’s success in luring big pharma,” stating, “Ireland was very smart. They took our pharmaceutical companies away from presidents that didn’t know what they were doing and its too bad that happened.”
Official data indicates that Ireland exports approximately €50bn (£42bn) worth of medicines globally each year. Regan notes that many of these exports “never touch Irish soil.”
He elaborates, “Without these accounting-based exports, Ireland’s trade surplus would be much smaller. The companies may not disappear but their taxable profits in might.”
Profit Shifting and “Phantom exports”
Regan explains that the “massive deficit” Trump referenced is partly attributable to “profit shifting,” a practice where companies manufacture drugs outside Ireland but book profits there due to legal ownership or intellectual property being held in Ireland.
He suggests, “One could argue that up to half of the corporate tax take in Ireland is volatile and based on, quite frankly, phantom exports.”
Regan believes that Trump’s team is well aware of this issue and could address the imbalance through tariffs and amendments to the Tax Cuts and Jobs Act, US legislation introduced in 2018.
“It is designed to try to incentivise a lot of that profit to be relocated back into the USA,and in some cases it was,but there’s a lot of loopholes in that legislation,which meant that it was much more profitable for the pharmaceutical sector,in particular,to move more profit into Ireland.”
He adds, “trump and his team are very aware of that and could just tweak the tax code to put pressure on the companies to [move] more profit to the US.”
Dermot O’Leary, an economist with Goodbody stockbrokers in Dublin, concurs that repatriating tax revenue would be a faster process than relocating jobs.
O’Leary states, “From a manufacturing point of view, it takes a lot more than a four-year presidential term to actually find the land, put the plan in place, get the planning, build the factory, get the skills in place. But what can happen a lot more quickly is in relation to the profits generated and the intellectual property.”
Ireland’s Vulnerability
He highlights a dual threat to Ireland: a potential drop in the US corporate tax rate from 21% to 15%, mirroring Dublin’s rate, which would eliminate ireland’s tax advantage. Additionally, Trump could reduce tax rates on profits from IP activity (currently at 10.5% and 13.125%) to incentivize US companies to return.
Successive Irish ministers have acknowledged Ireland’s vulnerability.Former Taoiseach Simon Harris cautioned as recently as November that Ireland could “lose €10bn in corporate tax” if just three US multinationals were repatriated to the US.
Official data from earlier this year reveals that Ireland collected €28bn in corporate tax last year, coinciding with highly profitable multinationals “onshoring” their valuable IP assets to ireland.
The country’s fiscal watchdog estimates that 75% of all corporate tax is paid by large US multinationals,with three firms alone responsible for almost 40%.
Regarding tariffs, oliver O’Connor, the chief executive of the pharma trade body the Irish Pharmaceutical Healthcare association, told RTÉ he was “confident” the 50,000-strong workforce in the sector in Ireland would be there in five years’ time.
TrumpS Stance on US Pharma in Ireland: Q&A
This article explores Donald Trump’s views on US pharmaceutical companies operating in Ireland, focusing on profit shifting, potential impacts on jobs, and Ireland’s vulnerability.
1. What is donald Trump’s issue with US pharmaceutical companies in Ireland?
Donald Trump has criticized Ireland for attracting US pharmaceutical companies, accusing the country of “stealing” american tax revenue and jobs.During a meeting with the Irish Taoiseach, Micheál Martin, he specifically targeted Ireland’s success in luring big pharma. He believes past US presidents were unaware of what they were doing when these companies moved operations.
2. Will US pharma companies close plants in Ireland due to Trump’s stance?
Experts suggest that US pharmaceutical companies are more likely to shift profits back to the United States rather than close their manufacturing plants in Ireland. Dermot O’Leary, an economist with Goodbody stockbrokers in Dublin, believes repatriating profits is a faster and more feasible process than relocating manufacturing operations.
3. What is “profit shifting” or “phantom exports,” and how does it relate to US pharma in Ireland?
“Profit shifting,” also referred to as “phantom exports”, is a practice where companies book profits in Ireland due to legal ownership or intellectual property being held there, even if the actual manufacturing occurs elsewhere.Aidan Regan, a professor of political economy at University College dublin, explains that this accounting-based export considerably inflates Ireland’s trade surplus. He estimates that up to half of Ireland’s corporate tax revenue may be based on these “phantom exports.”
4. How vulnerable is Ireland to changes in US tax policy regarding pharma companies?
Ireland is considered vulnerable to changes in US tax policy. Former Taoiseach Simon Harris cautioned that Ireland could lose €10 billion in corporate tax if just three US multinationals were to repatriate to the US. Several factors contribute to this vulnerability:
Potential Drop in US Corporate Tax Rate: A reduction in the US corporate tax rate from 21% to 15% (mirroring Ireland’s rate) would eliminate Ireland’s tax advantage.
Reduced tax Rates on IP Activity: Trump could reduce tax rates on profits from intellectual property activity in the US, incentivizing companies to bring these assets back home.
Reliance on US Multinationals: 75% of all corporate tax in Ireland is paid by large US multinationals,with three firms alone responsible for almost 40%.
5. How could Trump address the trade imbalance with Ireland?
Aidan Regan believes that Trump’s team could address the trade imbalance through:
Tariffs: Imposing tariffs on goods or services from Ireland.
Amendments to the Tax Cuts and Jobs act: Modifying the Tax cuts and Jobs Act of 2018 to close loopholes that allow pharmaceutical companies to easily shift profits to Ireland.Tweaking the tax code could put pressure on companies to move more profit to the US.
6. What is the potential impact on jobs in the Irish pharmaceutical sector?
Oliver O’Connor, the chief executive of the pharma trade body, the Irish Pharmaceutical Healthcare Association, expresses confidence that the 50,000-strong workforce in the sector in Ireland will remain in place for the foreseeable future. However, other possibilities remain:
Based on a pressreader article, US pharmaceutical companies based in Ireland are more likely to shift profits back to the US than close manufacturing plants after Donald Trump accused Ireland of stealing American tax and jobs.
Major pharmaceutical companies with operations in Ireland have remained silent on their future following Trump’s statement about bringing manufacturing back to the US.
7. What do Irish exports of medicine look like?
Ireland exports approximately €50 billion (£42 billion) worth of medicines globally each year. According to professor Regan, it is indeed crucial to note that many of these exports “never touch Irish soil.”
8.How much corporate tax does ireland collect, and what role do US companies play?
Ireland collected €28 billion in corporate tax last year (data from earlier this year. A meaningful portion of this comes from US multinationals “onshoring” their valuable IP assets to Ireland. The country’s fiscal watchdog estimates that 75% of all corporate tax is paid by large US multinationals, with three firms alone responsible for almost 40%.
Key Information Summary: US Pharma in Ireland
| Aspect | Description |
| ————————— | ——————————————————————————————————————————————– |
| Trump’s Accusation | Ireland is “stealing” US tax revenue and jobs by attracting pharmaceutical companies. |
| Expert Opinion | Profit shifting is more likely than plant closures. |
| Profit Shifting | Booking profits in Ireland despite manufacturing occurring elsewhere. |
| *